Search Within

Gary Schwartz

Formats
  1. Journal Article (191)
  2. Meeting Abstract (190)
  3. Conference Paper (3)
  4. Book Section (1)
Groups
  1. Department of Medicine (215)
  2. Solid Tumor Oncology Division (205)
  3. Melanoma Disease Management Team (129)
  4. Center for Pancreatic Cancer Research (99)
  5. Gastrointestinal Oncology Service (99)
  6. GSK Faculty (91)

More Groups

People
  1. David Kelsen (79)
  2. Richard Carvajal (61)
  3. Manish Shah (41)
  4. Mark Dickson (40)
  5. Eileen O'Reilly (36)
  6. Monica Motwani (36)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2018 (2)
  4. 2016 (3)
  5. 2015 (5)
  6. 2014 (23)

More Years

Publications
  1. Journal of Clinical Oncology (103)
  2. Cancer Research (42)
  3. Clinical Cancer Research (39)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (30)
  5. Annals of Oncology (12)
  6. Cancer (12)

More Publications

Publishers
  1. American Association for Cancer Research (121)
  2. American Society of Clinical Oncology (105)
  3. Elsevier Inc. (20)
  4. Springer (20)
  5. Oxford University Press (16)
  6. Wiley Blackwell (15)

More Publishers

Results (385)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter random assignment phase II study of irinotecan and flavopiridol versus irinotecan alone for patients with p53 wild-type gastric adenocarcinoma (NCI 8060)
    Meeting Abstract

    Shah, M. A.; Smyth, E. C.; Shibata, S.; Yong, W.; Tang, L. H.; Janjigian, Y. Y.; Kelsen, D. P.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Direct visualization of circulating sarcoma cells by whole-blood fluoresence in situ hybridization
    Meeting Abstract

    Morozov, A.; Leversha, M.; Keohan, M.; D'Adamo, D. R.; Schwartz, G. K.; Meyers, P. A.; Maki, R. G.; Moore, M. A.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Immunologic response to xenogeneic gp100 DNA in melanoma patients: Comparison of particle-mediated epidermal delivery with intramuscular injection
    Meeting Abstract

    Ginsberg, B. A.; Wolchok, J. D.; Roman, R.; Gallardo, H. F.; Chapman, P. B.; Schwartz, G. K.; Carvajal, R. D.; Terzulli, S. L.; Bewkes, B. B.; Yuan, J. D.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I trial of pulse-dose vorinostat with flavopiridol in solid tumors
    Meeting Abstract

    Dickson, M. A.; Rathkopf, D. E.; Grant, S.; Roberts, J. D.; Reid, J. M.; Ames, M. M.; McGovern, R. M.; Gonen, M.; Dials, H. J.; Schwartz, G. K.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase
    Meeting Abstract

    Brega, N.; McArthur, G. A.; Britten, C.; Wong, S. G.; Wang, E.; Wilner, K. D.; Blasina, A.; Schwartz, G. K.; Gallo, J.; Tse, A. N.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • MK8745, an Aurora A kinase-specific inhibitor induces apoptosis in a p53-dependent manner
    Meeting Abstract

    Nair, J. S.; Schwartz, G. K.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • The MEK inhibitor AZD6244 is active in GNAQ mutant ocular melanoma cells
    Meeting Abstract

    Ambrosini, G.; Schwartz, G. K.
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Population pharmacokinetics of PD 0332991 in patients with advanced cancers
    Meeting Abstract

    Tortorici, M. A.; O'Dwyer, P.; LoRusso, P.; Schwartz, G.; Wilner, K.; Ruiz-Garcia, A.; Courtney, R.
    Clinical Pharmacology & Therapeutics (2010)

    Fulltext@MSK | Save
  • Population pharmacokinetic/pharmacodynamic evaluation of the effect of PD 0332991 on the QTC in patients with advanced cancer
    Meeting Abstract

    Shaik, N.; O'Dwyer, P.; LoRusso, P.; Schwartz, G.; Wilner, K.; Courtney, R.
    Clinical Pharmacology & Therapeutics (2010)

    Fulltext@MSK | Save
  • Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
    Journal Article

    Boss, D. S.; Schwartz, G. K.; Middleton, M. R.; Amakye, D. D.; Swaisland, H.; Midgley, R. S.; Ranson, M.; Danson, S.; Calvert, H.; Plummer, R.; more...
    Annals of Oncology (2010)

    Fulltext@MSK | Save